FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1946501884> ?p ?o ?g. }

• W1946501884 endingPage "1027" @default.
• W1946501884 startingPage "1027" @default.
• W1946501884 abstract "1027 Background: Tan (17-AAG) inhibits Hsp90 activity, resulting in degradation of client proteins including the HER2 receptor. A phase 1 trial demonstrated clinical activity of T + Tan in pts with HER2+ MBC (1 PR + 4 MRs in 15 pts with median of 2 prior T-based regimens; Modi et al, JCO 2007). Tan was initially a Cremophor-based product; a suspension became available and was substituted in this phase 2 trial. Methods: Eligible pts have HER2+ MBC and either PD within 3m following adjuvant T or PD following 1-line of T-based therapy for MBC. Pts receive standard weekly doses of T followed by Tan (450 mg/m2). Early pts received a Cremophor-based Tan product with antihistamine/steroid premeds. Later pts received the suspension Tan product without premeds. Primary endpoint: ORR by RECIST, disease status assessed every 8w. Results: As of 19Dec07, 29 pts enrolled (mean age 54 yrs, range 31–71; median KPS 90). 21 pts received Cremophor product; 8 pts received suspension product (4 pts crossed-over to the suspension product). 21 pts are evaluable for efficacy. Drug-related toxicity: fatigue (39%), diarrhea (33%), dizziness (24%) and headache (19%). Grade 3 drug-related toxicity in 3 pts (headache/fatigue; ↑ LFTs; and unsteady gait/euphoria, diarrhea), all reversible; 1 pt withdrawn for toxicity. Toxicities common to cytotoxic chemotherapy noticeably absent (alopecia, myelosuppression, peripheral neuropathy). Activity: 5 pts have a confirmed PR (1) 75% decrease in liver metastases, 8 months (m) on study; (2) 45% decrease in hilar node, 15+m/active; (3) 33% decrease in right breast lesion, 7+m /active; (4) 57% decrease in lymph nodes, liver, and left breast lesions, on study 7m; (5) 37% decrease in lymph nodes, 5+m/active. All 4 active pts maintained PR when cross-over to the new formulation. Two additional pts had MR with ↓ tumor markers (6 and 5 m); 5 pts had SD for 4, 4, 4+, 7 and 8 m. Conclusions: The combination of T + Tan is active in pts with HER2+ MBC with progression on T-based therapy (response rate of 24% and clinical benefit rate of 57%). Toxicity is very manageable. The newer suspension product produces a similar safety profile with responses maintained upon cross-over. Accrual continues on the suspension product. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Kosan Biosciences Kosan Biosciences Kosan Biosciences Kosan Biosciences" @default.
• W1946501884 created "2016-06-24" @default.
• W1946501884 creator A5001476155 @default.
• W1946501884 creator A5007464229 @default.
• W1946501884 creator A5008516584 @default.
• W1946501884 creator A5010393631 @default.
• W1946501884 creator A5029590188 @default.
• W1946501884 creator A5034917686 @default.
• W1946501884 creator A5058025297 @default.
• W1946501884 creator A5073488968 @default.
• W1946501884 creator A5089364285 @default.
• W1946501884 creator A5089612947 @default.
• W1946501884 date "2008-05-20" @default.
• W1946501884 modified "2023-10-17" @default.
• W1946501884 title "Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)" @default.
• W1946501884 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.1027" @default.
• W1946501884 hasPublicationYear "2008" @default.
• W1946501884 type Work @default.
• W1946501884 sameAs 1946501884 @default.
• W1946501884 citedByCount "42" @default.
• W1946501884 countsByYear W19465018842012 @default.
• W1946501884 countsByYear W19465018842013 @default.
• W1946501884 countsByYear W19465018842015 @default.
• W1946501884 countsByYear W19465018842019 @default.
• W1946501884 countsByYear W19465018842022 @default.
• W1946501884 crossrefType "journal-article" @default.
• W1946501884 hasAuthorship W1946501884A5001476155 @default.
• W1946501884 hasAuthorship W1946501884A5007464229 @default.
• W1946501884 hasAuthorship W1946501884A5008516584 @default.
• W1946501884 hasAuthorship W1946501884A5010393631 @default.
• W1946501884 hasAuthorship W1946501884A5029590188 @default.
• W1946501884 hasAuthorship W1946501884A5034917686 @default.
• W1946501884 hasAuthorship W1946501884A5058025297 @default.
• W1946501884 hasAuthorship W1946501884A5073488968 @default.
• W1946501884 hasAuthorship W1946501884A5089364285 @default.
• W1946501884 hasAuthorship W1946501884A5089612947 @default.
• W1946501884 hasConcept C121608353 @default.
• W1946501884 hasConcept C126322002 @default.
• W1946501884 hasConcept C141071460 @default.
• W1946501884 hasConcept C2775930923 @default.
• W1946501884 hasConcept C2777063308 @default.
• W1946501884 hasConcept C29730261 @default.
• W1946501884 hasConcept C530470458 @default.
• W1946501884 hasConcept C71924100 @default.
• W1946501884 hasConcept C90924648 @default.
• W1946501884 hasConceptScore W1946501884C121608353 @default.
• W1946501884 hasConceptScore W1946501884C126322002 @default.
• W1946501884 hasConceptScore W1946501884C141071460 @default.
• W1946501884 hasConceptScore W1946501884C2775930923 @default.
• W1946501884 hasConceptScore W1946501884C2777063308 @default.
• W1946501884 hasConceptScore W1946501884C29730261 @default.
• W1946501884 hasConceptScore W1946501884C530470458 @default.
• W1946501884 hasConceptScore W1946501884C71924100 @default.
• W1946501884 hasConceptScore W1946501884C90924648 @default.
• W1946501884 hasIssue "15_suppl" @default.
• W1946501884 hasLocation W19465018841 @default.
• W1946501884 hasOpenAccess W1946501884 @default.
• W1946501884 hasPrimaryLocation W19465018841 @default.
• W1946501884 hasRelatedWork W2088620963 @default.
• W1946501884 hasRelatedWork W2169663330 @default.
• W1946501884 hasRelatedWork W2170271130 @default.
• W1946501884 hasRelatedWork W2399080192 @default.
• W1946501884 hasRelatedWork W2402743643 @default.
• W1946501884 hasRelatedWork W2790917413 @default.
• W1946501884 hasRelatedWork W3099142388 @default.
• W1946501884 hasRelatedWork W3156970501 @default.
• W1946501884 hasRelatedWork W4205490314 @default.
• W1946501884 hasRelatedWork W4313063054 @default.
• W1946501884 hasVolume "26" @default.
• W1946501884 isParatext "false" @default.
• W1946501884 isRetracted "false" @default.
• W1946501884 magId "1946501884" @default.
• W1946501884 workType "article" @default.